Recent Clinical Trials of Antiplatelet Therapy in Secondary Stroke Prevention: Expectations and Results for Application in Primary Care Settings

American Journal of Medicine

Volumn 122, Issue 4 SUPPL. 2, 2009, Pages

  Lutsep, Helmi L ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Antiplatelet therapy; Prevention; Primary care; Secondary stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; CLOPIDOGREL; DIPYRIDAMOLE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; IRBESARTAN; ORAL ANTIDIABETIC AGENT; TELMISARTAN; TICLOPIDINE; WARFARIN;

ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIABETES MELLITUS; DIARRHEA; DRUG EFFICACY; EMBOLISM PREVENTION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEART ATRIUM FIBRILLATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LIFESTYLE MODIFICATION; LOW DRUG DOSE; NEUTROPENIA; OUTCOME ASSESSMENT; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RECOMMENDED DRUG DOSE; RECURRENCE RISK; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; SECONDARY PREVENTION; STROKE; THROMBOSIS PREVENTION; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT INDICATION;

ANTICOAGULANTS; CLINICAL TRIALS AS TOPIC; EVIDENCE-BASED MEDICINE; HUMANS; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; PRIMARY HEALTH CARE; STROKE;

EID: 63149087398     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2009.02.007     Document Type: Article

References (35)

1. Kikano G.E., and Brown M.T. Antiplatelet therapy for atherothrombotic disease: an update for the primary care physician. Mayo Clin Proc 82 (2007) 583-593
2. Albers G.W., Amarenco P., Easton J.D., Sacco R.L., and Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 suppl (2004) 483S-512S
3. Sacco R.L., Adams R., Albers G., et al., American Heart Association/American Stroke Association, the Council on Cardiovascular Radiology and Intervention, and the American Academy of Neurology. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke, co-sponsored by the Council on Cardiovascular Radiology and Intervention. The American Academy of Neurology affirms the value of this guideline. Circulation 113 (2006) e409-e449
4. Johnston S.C., Nguyen-Huynh M.N., Schwarz M.E., et al. National Stroke Association guidelines for the management of transient ischemic attacks. Ann Neurol 60 (2006) 301-313
5. Elkind M.S. Implications of stroke prevention trials: treatment of global risk. Neurology 65 (2005) 17-21
6. Barnett H.J., Taylor D.W., Eliasziw M., et al. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. N Engl J Med 339 (1998) 1415-1425
7. ESPRIT Study Group. Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial. Lancet Neurol 6 (2007) 115-124
8. Mohr J.P., Thompson J.L., Lazar R.M., et al., Warfarin-Aspirin Recurrent Stroke Study Group. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 345 (2001) 1444-1451
9. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 (2002) 71-86
10. Miner J., and Hoffhines A. The discovery of aspirin's antithrombotic effects. Tex Heart Inst J 34 (2007) 179-186
11. Pettigrew L.C. Antithrombotic drugs for secondary stroke prophylaxis. Pharmacotherapy 21 (2001) 452-463
12. Albers G.W., Amarenco P., Easton J.D., Sacco R.L., and Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke. Chest 119 suppl (2001) 300S-320S
13. Eisert W.G. Dipyridamole. In: Michelson A.D. (Ed). Platelets. 2nd ed. (2006), Elsevier Science & Technology, Oxford, England 1165-1180
14. Muller T.H., Su C.A., Weisenberger H., et al. Dipyridamole alone or combined with low-dose acetylsalicylic acid inhibits platelet aggregation in human whole blood ex vivo. Br J Clin Pharmacol 30 (1990) 179-186
15. Bhatt D.L., Fox K.A., Hacke W., et al., CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354 (2006) 1706-1717
16. Nappi J., and Talbert R. Dual antiplatelet therapy for prevention of recurrent ischemic events. Am J Health Syst Pharm 59 (2002) 1723-1735
17. Algra A., and van Gijn J. Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia. J Neurol Neurosurg Psychiatry 60 (1996) 197-199
18. Johnson E.S., Lanes S.F., Wentworth III C.E., Satterfield M.H., Abebe B.L., and Dicker L.W. A metaregression analysis of the dose-response effect of aspirin on stroke. Arch Intern Med 159 (1999) 1248-1253
19. Campbell C.L., Smyth S., Montalescot G., and Steinhubl S.R. Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA 297 (2007) 2018-2024
20. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348 (1996) 1329-1339
21. Diener H.C., Cunha L., Forbes C., Sivenius J., Smets P., and Lowenthal A. European Stroke Prevention Study 2: dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 143 (1996) 1-13
22. European Stroke Prevention Study 2. Efficacy and safety data. J Neurol Sci 151 suppl (1997) S1-S77
23. De Schryver E.L., and European/Australian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT) group. Design of ESPRIT: an international randomized trial for secondary prevention after non-disabling cerebral ischaemia of arterial origin. Cerebrovasc Dis 10 (2000) 147-150
24. ESPRIT Study Group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 367 (2006) 1665-1673
25. Diener H.C., Bogousslavsky J., Brass L.M., et al., MATCH Investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high risk patients (MATCH): randomised, double-blind, placebo controlled trial. Lancet 364 (2004) 331-337
26. Connolly S., Pogue J., Hart R., et al., ACTIVE Writing Group on behalf of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 367 (2006) 1903-1912
27. Bhatt D.L., Flather M.D., Hacke W., et al., CHARISMA Investigators. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 49 (2007) 1982-1988
28. Albers G.W. Choice of endpoints in antiplatelet trials: which outcomes are most relevant to stroke patients?. Neurology 54 (2000) 1022-1028
29. Sacco R.L., Sivenius J., and Diener H.C. Efficacy of aspirin plus extended-release dipyridamole in preventing recurrent stroke in high-risk populations. Arch Neurol 62 (2005) 403-408
30. Liao J.K. Secondary prevention of stroke and transient ischemic attack: is more platelet inhibition the answer?. Circulation 115 (2007) 1615-1621
31. Diener H.C., Sacco R., Yusuf S., and Steering Committee and PRoFESS Study Group. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS). Cerebrovasc Dis 23 (2007) 368-380
32. Sacco R.L., Diener H.C., Yusuf S., et al., PRoFESS Study Group. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 359 (2008) 1238-1251
33. Secondary Prevention of Small Subcortical Strokes (SPS3) Trial. [ClinicalTrials.gov Website.] March 2007. http://ClinicalTrials.gov Accessed January 24, 2008. ClinicalTrials.gov Identifier NCT00059306
34. SPS3: Secondary Prevention of Small Subcortical Strokes (SPOTRIAS). Stroke Trials Registry. [The Internet Stroke Center at Washington University Website.]. http://www.strokecenter.org/trials/TrialDetail.aspx?tid=79 Accessed January 24, 2008. ISRCTN Identifier NCT00059306
35. Chimowitz M.I., Lynn M.J., Howlett-Smith H., et al., Warfarin-Aspirin Symptomatic Intracranial Disease Trial Investigators. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 352 (2005) 1305-1316